Drug Discovery

WuXi XDC, IntoCell partner for drug-linker technology and CRDMO services

WuXi XDC, a China-based CRDMO specialising in antibody drug conjugates (ADCs) and the broader bioconjugate market, has entered into a memorandum of understanding (MoU) with South Korea's IntoCell.

Innovent and SanegeneBio partner for hypertension drug development

Innovent Biologics has signed a partnership agreement with Sanegene Bio to jointly develop an angiotensinogen (AGT) directed siRNA drug candidate, SGB-3908, to treat hypertension.

LimmaTech, AbVacc sign licensing agreement for S. aureus vaccine candidate

LimmaTech Biologics and AbVacc have entered into a licensing agreement, under which the former will get exclusive rights for the continued development of the latter's multivalent toxoid vaccine candidate, LBT-SA7 (previously known as IBT-V02).

Aldevron signs agreement to acquire license to Codex HiCap RNA Polymerase

Aldevron, a US-based developer and manufacturer of plasmid DNA, RNA and proteins for the biotech industry, has signed an agreement with US-based enzyme engineering company Codexis to acquire global exclusive license to Codex HiCap RNA Polymerase.

Almirall signs alliance with etherna for new mRNA-based therapies

Pharmaceutical company focused on medical dermatology Almirall has signed a multi-target alliance with mRNA/LNP technology platform company etherna to discover and develop new mRNA-based therapies to address severe skin diseases, including non-melanoma skin cancer.

Rigel, MD Anderson partner to expand REZLIDHIA assessment in AML

Rigel Pharmaceuticals has entered into a multi-year strategic development collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) for expanding the assessment of REZLIDHIA (olutasidenib) in acute myeloid leukaemia (AML) and other haematologic cancers.

Phenomic AI, Astellas partner to develop solid tumour cell therapies

Phenomic AI (Phenomic) has announced a research collaboration with Astellas Pharma for the development of solid tumour cell therapies.

Evommune, Accutar to discover drug candidates for chronic inflammatory diseases

Evommune has entered into a new strategic partnership with Accutar Biotechnology to discover new small-molecule drug candidates for chronic inflammatory diseases.

Q32 Bio to merge with Homology Medicines

Biotechnology company Q32 Bio has signed an agreement to merge with Homology Medicines, in an all-stock transaction.